Company Filing History:
Years Active: 2022
Title: Matthias Lingemann: Innovator in Viral Infection Research
Introduction
Matthias Lingemann is a notable inventor based in Bethesda, MD, who has made significant contributions to the field of viral infection research. His innovative work focuses on the use of ouabain antagonists to inhibit viral infections, showcasing his commitment to advancing medical science.
Latest Patents
Lingemann holds a patent for the "Use of ouabain antagonists to inhibit viral infection." This patent outlines a method for inhibiting viral infections in subjects, particularly through the administration of a competitive antagonist of ouabain that binds to ATP1A1. This method is particularly effective in inhibiting respiratory syncytial virus infections.
Career Highlights
Matthias Lingemann is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His role at this prestigious institution allows him to engage in groundbreaking research that has the potential to impact public health significantly.
Collaborations
Lingemann collaborates with esteemed colleagues such as Peter L. Collins and Shirin Munir, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Matthias Lingemann's work exemplifies the intersection of innovation and medical research, particularly in the fight against viral infections. His contributions are vital to the ongoing efforts to develop effective treatments and improve health outcomes.